STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.

Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.

Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.

Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing the way for Amgen's acquisition of Horizon
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing path for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Amgen to present at Wells Fargo Healthcare Conference and Citi Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
Rhea-AI Summary
Amgen announces positive results from Phase 2 OCEAN(a)-DOSE study of olpasiran, showing a lasting effect on Lp(a) reduction nearly a year after the last dose. No new safety concerns identified. Amgen convenes LDL Awareness to Action Implementation Consortium to improve LDL-C testing and evidence-based treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Amgen's LUMAKRAS® (sotorasib) is set for review by the FDA Oncologic Drugs Advisory Committee for full approval in treating KRAS G12C-mutated NSCLC. LUMAKRAS has shown positive results in multiple studies and is approved in various markets. The comprehensive data package will be discussed at the meeting on Oct. 5, 2023. A PDUFA target action date of Dec. 24, 2023, has been set.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
Rhea-AI Summary
Amgen declares a $2.13 per share dividend for the third quarter of 2023, payable on September 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
dividends
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
-
Rhea-AI Summary
Amgen receives full FDA approval for BLINCYTO® (blinatumomab) for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in patients with minimal residual disease (MRD) at baseline after remission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

150.87B
536.44M
0.22%
82.06%
3.01%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS